Summary of findings for the effect of antituberculosis treatment compared with no antituberculosis treatment in infertile women with genital tuberculosis with structural damage
| Population | Infertile women with genital tuberculosis with structural damage | |||||
| Intervention | Antituberculosis treatment (orally isoniazid, rifampicin, pyrazinamide and ethambutol (HRZE) for 6–12 months). | |||||
| Comparator | No antituberculosis treatment | |||||
| Outcomes | No of participants (studies) | Antituberculosis treatment | No antituberculosis treatment | Relative effect (95% CI) | Absolute effects | Certainty of the evidence (GRADE) |
| Pregnancy follow-up: not detailed | 78 (1 non-RCT) | 11/46 (23.9%) | 19/32 (59.4%) | RR: 0.50 (0.30 to 0.83) | 297 fewer per 1000 (from 416 fewer to 101 fewer) | ⊕ΟΟΟ *,† Very low |
| Full-term pregnancy | The study did not report information about full-term pregnancy | |||||
| Abortion or intrauterine death | The study did not report information about abortion or intrauterine death | |||||
| Ectopic pregnancy | The study did not report information about ectopic pregnancy | |||||
| Adverse events follow-up: not detailed | The study did not report information about adverse events | |||||
*We downgraded two levels of evidence due to very serious risk of bias: Inadequate reporting of prospective data collection, failure to report details on consecutive patient inclusion, unbiased assessment of study endpoint, follow-up period, lost to follow-up, prospective calculation of study size, contemporaneous groups and adequate statistical analysis.
†We downgraded two levels of evidence due to very serious imprecision.
GRADE, Grading of Recommendations, Assessment, Development and Evaluations; non-RCT, non-randomised controlled trial; RR, risk ratio.